Beijing green bamboo AC Hib triple vaccine, a subsidiary of Zhifei biology, is about to obtain production approval

The AC Hib triple vaccine independently developed by Beijing green bamboo bio Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Chongqing Zhifei Biological Products Co., Ltd., is expected to receive production approval before and after the Spring Festival The vaccine is expected to go on the market this year, so the company began to plan and preheat the promotion of the vaccine in the second half of last year According to the website of the State Food and Drug Administration (CFDA), the review status of the AC meningococcal (combined) Haemophilus influenzae (combined) combined vaccine (i.e AC Hib triple vaccine) in Beijing green bamboo changed to "under approval" According to the review progress of other new drugs, Zhifei biology is expected to get the production approval of the vaccine before and after the Spring Festival In mid December last year, the head of Zhifei biology said at a strategic meeting of a securities firm that the AC Hib triple vaccine is an upgrade product of the existing Hib vaccine and AC group meningococcal vaccine, which can prevent the related diseases caused by group A, group C meningococci and Haemophilus influenzae type B at the same time, and can reduce the number of vaccinations The market price of the vaccine will not be less than 180 yuan / piece, and the market capacity is expected to be about 68 million pieces, with a high prospect The vaccine is also a heavy-duty vaccine product that the company has high hopes for A person close to Zhifei told the big smart news agency that in the fourth quarter of last year, the company's pressure on terminal products was not active compared with previous years, but focused on the preheating of the marketing and promotion of AC Hib triple vaccine "What we have learned from the sales staff is that three academic promotion activities have been arranged at the end of last year, and earlier preparations have been started since the second half of last year." A researcher who pays attention to Zhifei biology said that after the AC Hib triple vaccine was launched in 2014, it will bring greater flexibility to the company's performance, which is very worthy of expectation And the listing of independent products, due to its high gross profit, will also improve the company's overall gross profit level According to the above person in charge of Zhifei biology, there are 5 independent products and 3 agent products in the existing product structure Agency products contribute 60% of operating revenue, but only 40% of profits, mainly due to the low gross profit margin of agency products According to the company's 2013 China Daily, the gross profit of independent products is 89% and that of agency products is 38%.